There is no cost to participate in the BAN2401 Study. It is sponsored by a pharmaceutical company that makes the study compound - BAN2401.
To be enrolled in the BAN2401 Study, patients must have symptoms of early Alzheimer's disease.
To learn more about the BAN2401 Study, visit
BAN2401 Study,BAN2401,BAN2401 Research Study,BAN2401 clinical trial,BAN2401 Alzheimer's study,First Choice Neurology,Dr. Jeffrey Gelblum,Jeffrey Gelblum MD,Alzheimer's clinical trial,clinical trials,First Choice Neurology Research Studies,First Choice Neurology clinical trials,
0 Comments